Episode 11: The Changing Treatment Paradigm of HER2+ Metastatic Breast Cancer

Special HER2+ mBC Populations: HR+ or HER2-Low Patients

Dr. VK Gadi and expert panelists discuss the optimal management of patients with special subsets of HER2+ metastatic breast cancer, such as HR+ or HER2-low disease.

The University of Illinois Cancer Center serves as a Strategic Alliance Partner with OncLive. View our complete video library.

Translate »